ISIS 304801: Clinical Trials

7 trials of ISIS 304801, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 no longer available, 1 terminated. 4 Phase 3, 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 34Completed 3, Terminated 1
Phase 22Completed 1, Terminated 1
Phase 11Completed 1

Follow ISIS 304801: new trials by email Literature Review of ISIS 304801 trials Research Report on ISIS 304801

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers
Volanesorsen, Moxifloxacin, Placebo - Abnormalities, Cardiovascular
Phase 1CompletedIonis Pharmaceuticals, Inc.522016-09-192022-01-28
The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy
volanesorsen, Placebo - Familial Partial Lipodystrophy
Phase 2 / Phase 3TerminatedAkcea Therapeutics402015-12-282021-10-18
Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
ISIS 304801, Placebo - Lipodystrophy
Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)52015-12-232020-10-20
The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome
Volanesorsen - Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency
Phase 3CompletedAkcea Therapeutics682015-12-232021-08-26
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
Volanesorsen, Placebo - Hypertriglyceridemia
Phase 3CompletedIonis Pharmaceuticals, Inc.1142015-02-052022-04-13
The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
Volanesorsen, Placebo - Familial Chylomicronemia Syndrome
Phase 3CompletedIonis Pharmaceuticals, Inc.672014-12-012022-04-13
Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
Volanesorsen - Familial Chylomicronemia
No longer availableAkcea Therapeutics2021-09-16

Conditions studied

Familial hyperchylomicronemia syndrome (3)  ·  Hyperlipoproteinemia Type I (2)  ·  Hypertriglyceridemia (2)  ·  Cardiovascular Abnormalities (1)  ·  Dyslipidemias (1)  ·  Genetic Diseases, Inborn (1)  ·  Hyperlipidemias (1)  ·  Hyperlipoproteinemias (1)  ·  Lipid Metabolism Disorders (1)  ·  Lipid Metabolism, Inborn Errors (1)  ·  Lipodystrophy (1)  ·  Lipodystrophy, Familial Partial (1)  ·  Metabolic Diseases (1)  ·  Metabolism, Inborn Errors (1)

Sponsors

Akcea Therapeutics (3)  ·  Ionis Pharmaceuticals, Inc. (3)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)

Countries

United States (6)  ·  Canada (4)  ·  Germany (4)  ·  Netherlands (4)  ·  Brazil (3)  ·  France (3)  ·  United Kingdom (3)  ·  Israel (2)  ·  Italy (2)  ·  South Africa (2)  ·  Spain (2)  ·  Belgium (1)  ·  Hungary (1)  ·  Russia (1)

Top investigators

Rebecca J Brown, M.D. (1)

Results publications

PMID 37164837, PMID 27271183, PMID 29748148, PMID 31390500, PMID 33798466, PMID 36195542

NIH funding

2014 (2), 2015 (2)